![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
T Nakamura, A Hisaka, Y Sawasaki, Y Suzuki, T Fukami, K Ishikawa, M Yano and Y Sugiyama
Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., Japan.
The hepatic uptake mechanisms and pharmacokinetics of BQ-123, an anionic cyclopentapeptidic endothelin ET(A) receptor antagonist, were studied in rats. Elimination of BQ-123 from plasma after intravenous injection of the compound was very rapid as evidenced by high total body clearance (CLtot, 50 ml/min/kg), which is comparable with hepatic blood flow rate. Within 1 hr after injection, 86% of the dose was excreted as its intact form in the bile. BQ-123 was taken up extensively by isolated rat hepatocytes both Na(+)-dependently and Na(+)-independently. The Na(+)-dependent system transported BQ-123 with higher affinity than did the Na(+)-independent system (Km; 6 and 12 microM, respectively), but its capacity was lower (Vmax; 140 and 390 pmol/min/10(6) cells, respectively). Both uptake systems were found to be active transport systems because of explicit inhibition by metabolic inhibitors. BQ-485, an anionic linear tripeptide, strongly inhibited BQ- 123 uptake with Ki values of 1.6 and 2.5 microM for Na(+)-dependent and Na(+)-independent systems, respectively, whereas BQ-587, a cationic cyclopentapeptide, inhibited BQ-123 uptake only slightly. Considering this in vitro finding and the low in vivo CLtot of BQ-587 together, the carrier systems for BQ-123 seem to recognize negatively charged substances selectively. Both Na(+)-dependent and Na(+)-independent uptake of BQ-123 were competitively inhibited by a bile acid (taurocholate) and an organic anion (dibromosulfophthalein). The Ki values were comparable with the Km values of taurocholate and dibromosulfophthalein transport, which suggests that the Na(+)- dependent system corresponds to the bile acid transporter and that the Na(+)-independent system corresponds to the organic anion transporter.
This article has been cited by other articles:
|
|
 |
|
  H. Kouzuki, H. Suzuki, B. Stieger, P. J. Meier, and Y. Sugiyama Characterization of the Transport Properties of Organic Anion Transporting Polypeptide 1 (oatp1) and Na+/Taurocholate Cotransporting Polypeptide (Ntcp): Comparative Studies on the Inhibitory Effect of their Possible Substrates in Hepatocytes and cDNA-Transfected COS-7 Cells J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 505 - 511. [Abstract] [Full Text]
|
|
|
|
|
|
S. Akhteruzzaman, Y. Kato, H. Kouzuki, H. Suzuki, A. Hisaka, B. Stieger, P. J. Meier, and Y. Sugiyama Carrier-Mediated Hepatic Uptake of Peptidic Endothelin Antagonists in Rats J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1107 - 1115. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. Niinuma, Y. Kato, H. Suzuki, C. A. Tyson, V. Weizer, J. E. Dabbs, R. Froehlich, C. E. Green, and Y. Sugiyama Primary active transport of organic anions on bile canalicular membrane in humans Am J Physiol Gastrointest Liver Physiol, May 1, 1999; 276(5): G1153 - G1164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kato, S. Akhteruzzaman, A. Hisaka, and Y. Sugiyama Hepatobiliary Transport Governs Overall Elimination of Peptidic Endothelin Antagonists in Rats J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 568 - 574. [Abstract] [Full Text]
|
|
|
|
|
|
S. Akhteruzzaman, Y. Kato, A. Hisaka, and Y. Sugiyama Primary Active Transport of Peptidic Endothelin Antagonists by Rat Hepatic Canalicular Membrane J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 575 - 581. [Abstract] [Full Text]
|
|
|
|
|
|
H. Kouzuki, H. Suzuki, K. Ito, R. Ohashi, and Y. Sugiyama Contribution of Organic Anion Transporting Polypeptide to Uptake of Its Possible Substrates into Rat Hepatocytes J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 627 - 634. [Abstract] [Full Text]
|
|
|
|
|
|
H. Ishizuka, K. Konno, H. Naganuma, K. Nishimura, H. Kouzuki, H. Suzuki, B. Stieger, P. J. Meier, and Y. Sugiyama Transport of Temocaprilat into Rat Hepatocytes: Role of Organic Anion Transporting Polypeptide J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 37 - 42. [Abstract] [Full Text]
|
|
|
|
|
|
T. Kitazawa, T. Terasaki, H. Suzuki, A. Kakee, and Y. Sugiyama Efflux of Taurocholic Acid Across the Blood-Brain Barrier: Interaction with Cyclic Peptides J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 890 - 895. [Abstract] [Full Text]
|
|
|
|
|
|
H. Kouzuki, H. Suzuki, K. Ito, R. Ohashi, and Y. Sugiyama Contribution of Sodium Taurocholate Co-Transporting Polypeptide to the Uptake of Its Possible Substrates Into Rat Hepatocytes J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 1043 - 1050. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Yamada, K. Niinuma, M. Lemaire, T. Terasaki, and Y. Sugiyama CARRIER-MEDIATED HEPATIC UPTAKE OF THE CATIONIC CYCLOPEPTIDE, OCTREOTIDE, IN RATS. Comparison between In Vivo and In Vitro Drug Metab. Dispos., May 1, 1997; 25(5): 536 - 543. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
